Physician profile
Eric Lara
NPI 1245944198
$7,973.50
in general payments reported to CMS, 2019-2025
41 companies · $4,550 in 2025
The $4,550 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $3,186 · 2025: $4,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,973.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.21 | 2023-2025 | |
| Amgen INC. | $824.66 | 2023-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $691.27 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $628.30 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $500.82 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.25 | 2024-2025 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $382.75 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $304.79 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $289.13 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $284.21 | 2025 | Tymlos |
| Axsome Therapeutics, INC. | $224.36 | 2024-2025 | Auvelity |
| Cequr Corporation | $193.15 | 2023-2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $168.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $156.03 | 2024-2025 | |
| Exact Sciences Corporation | $142.00 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.